CT-Cann2019 — The International Congress on Clinical Trials in Cannabis

It is our pleasure to warmly invite you to participate in the upcoming International Congress on Clinical Trials in Cannabis (CT-Cann2019), which will take place on 24-25 October 2019 in London, UK. The endocannabinoid system is involved in numerous physiological and behavioral processes and, as such, has potential therapeutic implications relevant to many human diseases. Accordingly, in recent years there has been intense interest in the study and application of cannabinoid therapy in almost all areas of clinical medicine. However, while cannabinoids undoubtedly present us with many promising prospects and opportunities, translational and clinical cannabinoid research is, for the most part, still in its infancy. CT-Cann2019 is an international meeting that will bring together leading researchers, clinicians, industry professionals and other related experts to discuss ways of improving current research strategies in this rapidly evolving field. We will touch, among other things, on basic and clinical methodologies, regulatory and legal issues, pharmacological considerations, and technological advancements related to cannabinoid administration. CT-Cann2019 will thus inform participants of the latest evidence and concepts regarding cannabinoid therapy, promote an exchange of ideas and practices in clinical trials on cannabis, and will undoubtedly spark many engaging and lively debates.

Topics: Phytocannabinoid study – strains, chemovars, entourage and molecules, Pharamacokinetics and pharmacodynamics of cannabinoids, Prediction of response to cannabinoid treatment, Clinical trials targeting Pain, GI Disorders, Palliative Care, Psychiatry and Neurological disorders, New designs for cannabis clinical trials (including pragmatic trials and n=1), Clinical Registries, Observational / Epidemiological studies: findings, interpretations, plans, Phase 2/3/4 study findings and designs (including special populations), Meta- and composite- analyses: findings and methodology, Regulatory, licensing, and development programme issues and plans, Cannabinoid trial best conduct including GCP and site training, Assessing safety of cannabinoid medications, Innovative route of administration (ROA) and titration technologies, Big data and cannabis, Cannabinoids and Opioids